QSAM Biosciences
  • About
    • Our Story
    • Leadership
    • Contact Us
  • Technology
    • CycloSam®
    • Publications
  • Pipeline
    • Metastatic Bone Cancers
    • Osetosarcoma/Ewing’s Sarcoma
    • Bone Marrow Ablation
  • Investors
    • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Forward-Looking Statements
    • Code of Ethics
  • Investors
  • About
  • Technology
  • Pipeline
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 17, 2022 8:00am EDT

QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

Apr 28, 2022 7:00am EDT

QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer

Apr 12, 2022 8:00am EDT

QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®

Mar 09, 2022 4:30pm EST

QSAM Biosciences Announces Reverse Stock Split Effective March 10, 2022

Feb 02, 2022 8:30am EST

QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma

Jan 25, 2022 8:30am EST

QSAM Biosciences Appoints Adriann Sax to Board of Directors

Dec 01, 2021 9:00am EST

QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer

Aug 25, 2021 9:00am EDT

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

Aug 18, 2021 9:00am EDT

QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma

Aug 11, 2021 9:00am EDT

QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets

  • 1
  • 2
  • 3
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Return to main site

Contact Us

  • info@qsambio.com
  • (512) 343-4558
  • 9442 N Capital of Texas Hwy, Plaza 1, Ste 500 Austin, TX 78759

© Copyright 2022 QSAM Biosciences, Inc. | All Rights Reserved. | Privacy Policy | Terms 
Cyclosam® is a registered trademark of IGL Pharma, Inc., a development partner of QSAM Therapeutics, Inc.